Does the media refer more to BRNS or BNR?

In the previous week, Barinthus Biotherapeutics had 10 more articles in the media than Burning Rock Biotech. MarketBeat recorded 13 mentions for Barinthus Biotherapeutics and 3 mentions for Burning Rock Biotech. Barinthus Biotherapeutics' average media sentiment score of 0.90 beat Burning Rock Biotech's score of 0.63 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Barinthus Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Burning Rock Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BRNS or DTSQ?

Barinthus Biotherapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 473.89%. Given Barinthus Biotherapeutics' higher possible upside, research analysts clearly believe Barinthus Biotherapeutics is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Barinthus Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, BRNS or DTSQ?

DT Cloud Star Acquisition has lower revenue, but higher earnings than Barinthus Biotherapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Barinthus Biotherapeutics $14.97M 1.90 -$66.43M -$1.03 N/A DT Cloud Star Acquisition N/A N/A N/A N/A N/A

Is BRNS or DTSQ more profitable?

DT Cloud Star Acquisition's return on equity of 0.00% beat Barinthus Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Barinthus Biotherapeutics N/A -59.15% -43.80% DT Cloud Star Acquisition N/A N/A N/A

Is KLRS or BRNS more profitable?

Barinthus Biotherapeutics' return on equity of -59.15% beat Kalaris Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kalaris Therapeutics N/A -71.71% -42.95% Barinthus Biotherapeutics N/A -59.15% -43.80%

Does the media prefer KLRS or BRNS?

In the previous week, Barinthus Biotherapeutics had 10 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 13 mentions for Barinthus Biotherapeutics and 3 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.96 beat Barinthus Biotherapeutics' score of 0.90 indicating that Kalaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kalaris Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Barinthus Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ATRA or BRNS?

In the previous week, Barinthus Biotherapeutics had 6 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 13 mentions for Barinthus Biotherapeutics and 7 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.95 beat Barinthus Biotherapeutics' score of 0.90 indicating that Atara Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atara Biotherapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Barinthus Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Barinthus Biotherapeutics (BRNS) Competitors

$0.70 -0.05 (-6.61%)

As of 04:00 PM Eastern

Compare

BRNS vs. YARW, BNR, DTSQ, KLRS, and ATRA

Should you buy Barinthus Biotherapeutics stock or one of its competitors? Barinthus Biotherapeutics's main competitors and comparable companies include Yarrow Bioscience (YARW), Burning Rock Biotech (BNR), DT Cloud Star Acquisition (DTSQ), Kalaris Therapeutics (KLRS), and Atara Biotherapeutics (ATRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Barinthus Biotherapeutics compare to Yarrow Bioscience?

Yarrow Bioscience (NASDAQ:YARW) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

83.8% of Yarrow Bioscience shares are owned by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. 3.0% of Yarrow Bioscience shares are owned by insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Yarrow Bioscience has a beta of 1.95, indicating that its share price is 95% more volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.39, indicating that its share price is 139% less volatile than the broader market.

Yarrow Bioscience currently has a consensus price target of $58.00, indicating a potential upside of 75.97%. Barinthus Biotherapeutics has a consensus price target of $4.00, indicating a potential upside of 473.89%. Given Barinthus Biotherapeutics' higher probable upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Yarrow Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yarrow Bioscience	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Barinthus Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Barinthus Biotherapeutics had 11 more articles in the media than Yarrow Bioscience. MarketBeat recorded 13 mentions for Barinthus Biotherapeutics and 2 mentions for Yarrow Bioscience. Barinthus Biotherapeutics' average media sentiment score of 0.90 beat Yarrow Bioscience's score of 0.44 indicating that Barinthus Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Yarrow Bioscience	Neutral
Barinthus Biotherapeutics	Positive

Barinthus Biotherapeutics has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Barinthus Biotherapeutics' return on equity of -59.15% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%

Yarrow Bioscience has higher earnings, but lower revenue than Barinthus Biotherapeutics. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yarrow Bioscience	$570K	154.39	-$26.48M	-$14.64	N/A
Barinthus Biotherapeutics	$14.97M	1.90	-$66.43M	-$1.03	N/A

Summary

Barinthus Biotherapeutics beats Yarrow Bioscience on 10 of the 16 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Burning Rock Biotech?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

In the previous week, Barinthus Biotherapeutics had 10 more articles in the media than Burning Rock Biotech. MarketBeat recorded 13 mentions for Barinthus Biotherapeutics and 3 mentions for Burning Rock Biotech. Barinthus Biotherapeutics' average media sentiment score of 0.90 beat Burning Rock Biotech's score of 0.63 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Barinthus Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Burning Rock Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Barinthus Biotherapeutics has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -11.57%. Burning Rock Biotech's return on equity of -10.98% beat Barinthus Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%
Burning Rock Biotech	-11.57%	-10.98%	-7.33%

Barinthus Biotherapeutics has a beta of -0.39, indicating that its share price is 139% less volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.34, indicating that its share price is 34% more volatile than the broader market.

Burning Rock Biotech has higher revenue and earnings than Barinthus Biotherapeutics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.90	-$66.43M	-$1.03	N/A
Burning Rock Biotech	$77.16M	1.29	-$7.92M	-$0.82	N/A

25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are held by institutional investors. 8.5% of Barinthus Biotherapeutics shares are held by insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Barinthus Biotherapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 473.89%. Given Barinthus Biotherapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Barinthus Biotherapeutics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Barinthus Biotherapeutics and Burning Rock Biotech tied by winning 8 of the 16 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to DT Cloud Star Acquisition?

Barinthus Biotherapeutics (NASDAQ:BRNS) and DT Cloud Star Acquisition (NASDAQ:DTSQ) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Barinthus Biotherapeutics has a beta of -0.39, meaning that its share price is 139% less volatile than the broader market. Comparatively, DT Cloud Star Acquisition has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market.

Barinthus Biotherapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 473.89%. Given Barinthus Biotherapeutics' higher possible upside, research analysts clearly believe Barinthus Biotherapeutics is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

DT Cloud Star Acquisition has lower revenue, but higher earnings than Barinthus Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.90	-$66.43M	-$1.03	N/A
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A

In the previous week, Barinthus Biotherapeutics had 10 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 13 mentions for Barinthus Biotherapeutics and 3 mentions for DT Cloud Star Acquisition. DT Cloud Star Acquisition's average media sentiment score of 1.07 beat Barinthus Biotherapeutics' score of 0.90 indicating that DT Cloud Star Acquisition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Barinthus Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DT Cloud Star Acquisition	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DT Cloud Star Acquisition's return on equity of 0.00% beat Barinthus Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%
DT Cloud Star Acquisition	N/A	N/A	N/A

25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. 8.5% of Barinthus Biotherapeutics shares are owned by company insiders. Comparatively, 52.9% of DT Cloud Star Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Barinthus Biotherapeutics and DT Cloud Star Acquisition tied by winning 5 of the 10 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Kalaris Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

In the previous week, Barinthus Biotherapeutics had 10 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 13 mentions for Barinthus Biotherapeutics and 3 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.96 beat Barinthus Biotherapeutics' score of 0.90 indicating that Kalaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kalaris Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Barinthus Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kalaris Therapeutics has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.39, indicating that its share price is 139% less volatile than the broader market.

Kalaris Therapeutics has higher earnings, but lower revenue than Barinthus Biotherapeutics. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A
Barinthus Biotherapeutics	$14.97M	1.90	-$66.43M	-$1.03	N/A

Barinthus Biotherapeutics' return on equity of -59.15% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-71.71%	-42.95%
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%

66.1% of Kalaris Therapeutics shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 68.1% of Kalaris Therapeutics shares are held by insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Kalaris Therapeutics presently has a consensus price target of $18.75, suggesting a potential upside of 364.11%. Barinthus Biotherapeutics has a consensus price target of $4.00, suggesting a potential upside of 473.89%. Given Barinthus Biotherapeutics' higher probable upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than Kalaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Barinthus Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Kalaris Therapeutics beats Barinthus Biotherapeutics on 9 of the 15 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

Atara Biotherapeutics has higher earnings, but lower revenue than Barinthus Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$6.19M	14.42	$32.69M	-$1.18	N/A
Barinthus Biotherapeutics	$14.97M	1.90	-$66.43M	-$1.03	N/A

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Barinthus Biotherapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -269.42%. Barinthus Biotherapeutics' return on equity of -59.15% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%

Atara Biotherapeutics presently has a consensus target price of $9.50, suggesting a potential upside of 6.74%. Barinthus Biotherapeutics has a consensus target price of $4.00, suggesting a potential upside of 473.89%. Given Barinthus Biotherapeutics' higher possible upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Barinthus Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Atara Biotherapeutics has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.39, suggesting that its stock price is 139% less volatile than the broader market.

In the previous week, Barinthus Biotherapeutics had 6 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 13 mentions for Barinthus Biotherapeutics and 7 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.95 beat Barinthus Biotherapeutics' score of 0.90 indicating that Atara Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Barinthus Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Atara Biotherapeutics and Barinthus Biotherapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Barinthus Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BRNS vs. The Competition

Export

Metric	Barinthus Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$28.47M	$3.92B	$7.12B	$12.85B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	-0.68	11.69	272.89	25.51
Price / Sales	1.90	1,396.48	686.41	123.12
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	0.38	16.81	11.06	6.34
Net Income	-$66.43M	-$22.71M	$3.47B	$349.45M
7 Day Performance	15.97%	2.89%	1.28%	-0.10%
1 Month Performance	24.96%	13.06%	8.29%	4.36%
1 Year Performance	-37.99%	55.07%	24.29%	14.91%

Barinthus Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BRNS Barinthus Biotherapeutics	3.2884 of 5 stars	$0.70 -6.6%	$4.00 +473.9%	-33.6%	$28.47M	$14.97M	N/A	107	High Trading Volume
YARW Yarrow Bioscience	2.5858 of 5 stars	$39.63 +1.0%	$58.00 +46.4%	N/A	$104.79M	$570K	N/A	30	Short Interest Increase Gap Up
BNR Burning Rock Biotech	0.7691 of 5 stars	$10.44 +6.5%	N/A	+19.1%	$103.08M	$77.16M	N/A	1,390	Upcoming Earnings
DTSQ DT Cloud Star Acquisition	1.7095 of 5 stars	$11.37 +0.4%	N/A	+8.5%	$100.85M	N/A	N/A	N/A	Short Interest Decrease
KLRS Kalaris Therapeutics	2.69 of 5 stars	$4.08 -2.9%	$18.75 +359.6%	-1.2%	$99.98M	N/A	N/A	110	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BRNS) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Barinthus Biotherapeutics (BRNS) Competitors

BRNS vs. YARW, BNR, DTSQ, KLRS, and ATRA

How does Barinthus Biotherapeutics compare to Yarrow Bioscience?

Summary

How does Barinthus Biotherapeutics compare to Burning Rock Biotech?

Summary

How does Barinthus Biotherapeutics compare to DT Cloud Star Acquisition?

Summary

How does Barinthus Biotherapeutics compare to Kalaris Therapeutics?

Summary

How does Barinthus Biotherapeutics compare to Atara Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS vs. The Competition

Barinthus Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Barinthus Biotherapeutics (BRNS) Competitors

BRNS vs. YARW, BNR, DTSQ, KLRS, and ATRA

How does Barinthus Biotherapeutics compare to Yarrow Bioscience?

Do institutionals and insiders believe in YARW or BRNS?

Which has more volatility & risk, YARW or BRNS?

Do analysts recommend YARW or BRNS?

Does the media prefer YARW or BRNS?

Is YARW or BRNS more profitable?

Which has stronger valuation and earnings, YARW or BRNS?

Summary

How does Barinthus Biotherapeutics compare to Burning Rock Biotech?

Does the media refer more to BRNS or BNR?

Is BRNS or BNR more profitable?

Which has more volatility & risk, BRNS or BNR?

Which has preferable valuation and earnings, BRNS or BNR?

Do insiders & institutionals have more ownership in BRNS or BNR?

Do analysts rate BRNS or BNR?

Summary

How does Barinthus Biotherapeutics compare to DT Cloud Star Acquisition?

Which has more risk & volatility, BRNS or DTSQ?

Do analysts recommend BRNS or DTSQ?

Which has preferable earnings and valuation, BRNS or DTSQ?

Does the media favor BRNS or DTSQ?

Is BRNS or DTSQ more profitable?

Do institutionals & insiders hold more shares of BRNS or DTSQ?

Summary

How does Barinthus Biotherapeutics compare to Kalaris Therapeutics?

Does the media prefer KLRS or BRNS?

Which has more risk and volatility, KLRS or BRNS?

Which has higher earnings and valuation, KLRS or BRNS?

Is KLRS or BRNS more profitable?

Do institutionals and insiders have more ownership in KLRS or BRNS?

Do analysts recommend KLRS or BRNS?

Summary

How does Barinthus Biotherapeutics compare to Atara Biotherapeutics?

Which has stronger earnings and valuation, ATRA or BRNS?

Do institutionals and insiders hold more shares of ATRA or BRNS?

Is ATRA or BRNS more profitable?

Do analysts rate ATRA or BRNS?

Which has more risk and volatility, ATRA or BRNS?

Does the media refer more to ATRA or BRNS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS vs. The Competition

Barinthus Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools